We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Protalix’s Gaucher’s Treatment Gets FDA Fast Track
Protalix’s Gaucher’s Treatment Gets FDA Fast Track
August 28, 2009
The FDA has granted fast-track designation for Protalix BioTherapeutics’ Gaucher’s disease treatment, prGCD, as part of the agency’s push to address the shortage of the only approved drug for the illness, Genzyme’s Cerezyme.